Recursion Pharmaceuticals, INC.
SEC CIK 1601830 · RXRX · last insider filing 2026-06-22
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Hershberg Robert | Director | filed 2021 - 2026 |
| Sun Elaine D | Director | filed 2025 - 2026 |
| Li Dean Y | Director | filed 2021 - 2026 |
| Dar Zavain | Director | filed 2021 - 2026 |
| Borgeson Blake | Director | filed 2021 - 2026 |
| Michor Franziska | Director | filed 2024 - 2026 |
| Bumpus Namandje | Director | filed 2025 - 2026 |
| Gibson Christopher | Director · Chief Executive Officer | filed 2021 - 2026 |
| Khan Najat | Director · Chief R&D Commercial Officer | filed 2024 - 2026 |
| Burrell Terry-Ann | Director | filed 2021 - 2024 |
| Chavez R. Martin | Director | filed 2021 - 2024 |
| Bogue Zachary | Director | filed 2021 - 2023 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Taylor Ben R | Chief Financial Officer | filed 2024 - 2026 |
| Hallett David | Chief Scientific Officer | filed 2026 - 2026 |
| Mauro David J | Chief Medical Officer | filed 2023 - 2024 |
| Secora Michael | Chief Financial Officer | filed 2021 - 2024 |
| Marriott Tina | President and COO | filed 2021 - 2024 |
| Virani Shafique | Chief Corp. Dev. Officer | filed 2021 - 2024 |
| Doyle Ramona | Chief Medical Officer | filed 2021 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.